Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Receives $50.33 Average PT from Brokerages

Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been assigned a consensus rating of “Hold” from the eleven analysts that are currently covering the stock, Marketbeat reports. Eight investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $50.33.

Several research analysts have weighed in on the company. HC Wainwright lowered Alpine Immune Sciences from a “buy” rating to a “neutral” rating in a research report on Thursday, April 11th. Wedbush downgraded Alpine Immune Sciences from an “outperform” rating to a “neutral” rating in a research note on Thursday, April 11th. Guggenheim began coverage on shares of Alpine Immune Sciences in a research note on Tuesday, April 9th. They set a “buy” rating and a $55.00 target price for the company. TD Cowen reiterated a “hold” rating on shares of Alpine Immune Sciences in a research report on Tuesday, April 16th. Finally, SVB Leerink lowered shares of Alpine Immune Sciences from an “outperform” rating to a “market perform” rating and lifted their target price for the company from $42.00 to $65.00 in a research report on Friday, April 12th.

Institutional Trading of Alpine Immune Sciences

Hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new stake in Alpine Immune Sciences in the 3rd quarter valued at about $114,000. Bank of New York Mellon Corp lifted its holdings in Alpine Immune Sciences by 1.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 92,723 shares of the biotechnology company’s stock worth $1,062,000 after buying an additional 1,216 shares in the last quarter. Barclays PLC boosted its position in Alpine Immune Sciences by 44.3% in the 3rd quarter. Barclays PLC now owns 9,126 shares of the biotechnology company’s stock valued at $104,000 after buying an additional 2,801 shares during the last quarter. New York State Common Retirement Fund increased its stake in shares of Alpine Immune Sciences by 75.8% in the 3rd quarter. New York State Common Retirement Fund now owns 9,634 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 4,155 shares during the period. Finally, Swiss National Bank bought a new stake in shares of Alpine Immune Sciences during the third quarter worth $483,000. Institutional investors and hedge funds own 75.17% of the company’s stock.

Alpine Immune Sciences Price Performance

ALPN opened at $64.55 on Friday. The company has a market capitalization of $4.23 billion, a price-to-earnings ratio of -100.86 and a beta of 1.14. Alpine Immune Sciences has a 1-year low of $6.71 and a 1-year high of $64.70. The business has a 50 day moving average price of $41.49 and a two-hundred day moving average price of $25.72.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.47. The company had revenue of $30.85 million for the quarter, compared to the consensus estimate of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. Equities analysts expect that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.